MedTrace Logo

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

NCT06446388 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2024-06-06

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of QLS31905 and/or QL1706 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

QLS31905

Administered as an intravenous infusion.

DRUG

Oxaliplatin

130 mg/m2, intravenous infusion, D1, up to 8 cycles.

DRUG

Capecitabine

1000 mg/m2, oral, bid, D1-D14

DRUG

Gemcitabine

1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.

DRUG

Cisplatin

25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.

DRUG

QL1706

5 mg/kg, intravenous infusion,D1

DRUG

Chemotherapy drug

Standard chemotherapy recommended by guidelines.

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2026-06-30
Completion
2027-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06446388 on ClinicalTrials.gov